Orphazyme CFO on failed trial: "Highly disappointing and highly surprising"
Monday's announcement that Orphazyme's main candidate, arimoclomol, for treating degenerative muscle disease IBM has not met its effect targets is highly disappointing and surprising, says the firm's CFO. Now, the company considers scaling back its efforts in the area.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
Read this article for free
Register with your E-mail. No credit card required.